Premium
Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality
Author(s) -
Baysal Vahide,
Yildirim Mehmet,
Ozcanli Cagnur,
Ceyhan A. Murat
Publication year - 2004
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2004.02123.x
Subject(s) - medicine , itraconazole , seborrheic dermatitis , dermatology , hydrocortisone , surgery , antifungal
Background Due to the high rate of recurrence, seborrheic dermatitis (SD) represents a therapeutic problem. Aim To evaluate the role of oral itraconazole in the treatment of SD. Patients and methods Thirty‐two patients with SD were enrolled in the study. All topical and oral treatments were stopped. The patients applied 1% hydrocortisone cream twice daily for 1 month. In addition, they took itraconazole, 200 mg/day, during the first week of the first month and then hydrocortisone cream was stopped and itraconazole (200 mg/day) was given on the first 2 days of the following 11 months. The patients were followed for 2 months without medicine. The severity score was measured at the initial evaluation, and at the first, 12th, and 14th months. Results Twenty‐eight patients completed the study. There was a statistically significant decrease in the mean severity score at the first, 12th, and 14th months. On the final evaluation at the 12th month, 19 of the 28 patients showed a complete improvement, and three patients showed a slight improvement. Conclusions This study indicates that itraconazole plays an important role in the treatment of SD.